Marshall Wace’s Evolent Health EVH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.79M Buy
785,012
+539,458
+220% +$1.71M ﹤0.01% 1846
2025
Q4
$982K Sell
245,554
-409,193
-62% -$2.27M ﹤0.01% 1946
2025
Q3
$5.54M Buy
654,747
+627,968
+2,345% +$6.09M 0.01% 1147
2025
Q2
$302K Buy
26,779
+729
+3% +$6.7K ﹤0.01% 2321
2025
Q1
$247K Sell
26,050
-68,270
-72% -$690K ﹤0.01% 2334
2024
Q4
$1.06M Buy
94,320
+29,328
+45% +$515K ﹤0.01% 1705
2024
Q3
$1.84M Buy
64,992
+584
+0.9% +$15.1K ﹤0.01% 1401
2024
Q2
$1.23M Buy
+64,408
New +$1.64M ﹤0.01% 1595
2023
Q1
Sell
-81,950
Closed -$2.3M 2786
2022
Q4
$2.3M Sell
81,950
-281,790
-77% -$8.08M 0.01% 1648
2022
Q3
$13.1M Sell
363,740
-59,995
-14% -$2.11M 0.03% 687
2022
Q2
$13M Buy
423,735
+59,705
+16% +$1.74M 0.03% 693
2022
Q1
$11.8M Buy
364,030
+134,134
+58% +$3.51M 0.02% 773
2021
Q4
$6.36M Buy
229,896
+187,347
+440% +$5.37M 0.01% 1182
2021
Q3
$1.32M Buy
+42,549
New +$1.02M 0.01% 1832
2019
Q4
Sell
-419,855
Closed -$3.02M 1797
2019
Q3
$3.02M Sell
419,855
-1,193,417
-74% -$8.56M 0.02% 643
2019
Q2
$12.8M Buy
1,613,272
+844,888
+110% +$10M 0.11% 220
2019
Q1
$9.67M Buy
+768,384
New +$12.2M 0.09% 270
2018
Q3
Sell
-52,623
Closed -$1.11M 1174
2018
Q2
$1.11M Buy
+52,623
New +$996K 0.02% 499
2016
Q4
Sell
-80,099
Closed -$1.97M 1007
2016
Q3
$1.97M Buy
+80,099
New +$1.87M 0.01% 600

Other funds holding EVH

Marshall Wace's EVH Position: Q1 2026 in Review

Marshall Wace increased its Evolent Health (EVH) stake by 220% in Q1 2026, buying an estimated $1.71M and bringing the position to 785,012 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

Marshall Wace first reported a position in EVH in Q3 2016 and has held it in 19 quarters since. The position peaked at $13.1M in Q3 2022. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Marshall Wace held 785,012 shares of Evolent Health worth $1.79M as of Q1 2026.
  • Marshall Wace bought 539,458 Evolent Health shares in Q1 2026, an estimated $1.71M.
  • Evolent Health made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1846 holding.
  • Marshall Wace first reported a position in Evolent Health in Q3 2016 and has held it in 19 quarters since.
  • Marshall Wace's Evolent Health position peaked at $13.1M in Q3 2022.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.